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Abstract. – Chronic obstructive pulmonary
disease (COPD) and asthma are lung inflammatory
diseases that represent major public health prob-
lems. The primary, and often unique, method to
evaluate lung function is spirometry, which re-
flects disease severity rather than disease activity.
Moreover, its measurements strictly depend on pa-
tient’s compliance, physician’s expertise and data
interpretation. The limitations of clinical history
and pulmonary function tests have encouraged fo-
cusing on new possible tracers of diseases.
The increase of the inflammatory response in
the lungs represents an early pathological event,
so biological markers related to inflammation
may play key roles in earlier diagnosis, evalua-
tion of functional impairment and prognosis.
Biomarkers are measurable indicators associ-
ated with the presence and/or severity of a bio-
logical or pathogenic process, which may predict
functional impairment, prognosis and response
to therapy.
The traditional approach based on invasive
techniques (bronchoalveolar lavage and biopsies)
may be replaced, at least in part, by using less in-
vasive methods to collect specimens (sputum and
blood), in which biomarkers could be measured.
Proteomics, by the association between different
protein profiles and pathogenic processes, is gain-
ing an important role in pulmonary medicine allow-
ing a more precise discrimination between pa-
tients with different outcomes and response to
therapy. The aim of this review was to evaluate the
use of biomarkers of airway inflammation in the
context of both research and clinical practice.
Key words:
Asthma, COPD, Biomarkers, Early diagnosis, Prog-
nosis.
Corresponding Author: Gregorino Paone, MD; e-mail: rpaone1023@yahoo.com
European Review for Medical and Pharmacological Sciences
Blood and sputum biomarkers in COPD 
and asthma: a review
G. PAONE1,2, V. LEONE2, V. CONTI3, L. DE MARCHIS4, E. IALLENI2, 
C. GRAZIANI2, M. SALDUCCI5, M. RAMACCIA2, G. MUNAFÒ2
1Department of Cardiovascular, Respiratory, Nephrologic, Anesthesiologic and Geriatric Sciences, 
“Sapienza” University of Rome, Rome, Italy;
2Department of Respiratory Diseases, S. Camillo-Forlanini Hospital, Rome, Italy;
3Department of Respiratory Diseases, IRCCS San Raffaele Pisana, Rome, Italy;
4Department of Radiology, Oncology, and Pathology, “Sapienza” University of Rome, Rome, Italy;
5Department of Sense Organs, “Sapienza” University of Rome, Rome, Italy.
2016; 20: 698-708
Abbreviation list
BAL Broncoalveolar lavage 
BMI Body Mass Index
CC-10 Clara cell protein 10
CC-16 Clara cell protein-16
CCL-2 Chemokine (C-C motif) ligand 2
CCL-5 Chemokine (C-C motif) ligand 5
CCL-18 Chemokine (C-C motif) ligand 18
CD4+ Cluster of differentiation 4
CD-8+ Cluster of differentiation 8 
COPD Chronic obstructive pulmonary disease
CRP C reactive protein
CT Computer Tomography
CXCL1 Chemokine (C-X-C motif) ligand 1
CXCL8 Chemokine (C-X-C motif) ligand 8
CXCL9 Chemokine (C-X-C motif) ligand 9
CXCL10 Chemokine (C-X-C motif) ligand 10
CXCL11 Chemokine (C-X-C motif) ligand 11
DEFA1 Defensin, alpha 1
DEFA2 Defensin, alpha 2
ECP Eosinophil cationic protein 
EGFR Epidermal growth factor receptor 
FE (NO) Fractional exhaled nitric oxide
FEV1 Forced Expiratory Volume in the 1st second
FVC Forced Vital Capacity 
GM-CSF Granulocyte-macrophage colony stimulating factor 
GOLD Global Initiative for chronic Obstructive Lung Disease
GRO α Growth-related-oncogene-alpha
HNP Human Neutrophil Peptides
IFN Interferon
IgE Immunoglobulin E
IL-1α Interleukin 1alpha
IL-1β Interleukin 1beta
Il-1RA Interleukin 1 receptor antagonist
IL-2 Interleukin 2
IL-6 Interleukin 6
IL-8 Interleukin 8
IL-13 Interleukin 13
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IL-17 Interleukin 17 activated
IL-18 Interleukin 18
IL-β Interleukin beta
LTB4 Leukotriene B4
MCP-1 Monocyte chemoattractant protein-1 
MMP-12 Matrix metalloproteinase-12
MMP-1 Matrix metalloproteinase-1
MMP-7 Matrix metalloproteinase-7
MMP-8 Matrix metalloproteinase-8
MMP-9 Matrix metalloproteinase-9
MPO Myeloperoxidase
NE Neutrophil elastase
NIH National Institutes of Health
NO Nitric Oxide
PEF Peek expiratory flow
PRB4 Proline-rich protein 4 
PRH1 Proline-rich protein HaeIII subfamily 1
PRH2 Proline-rich protein HaeIII subfamily 2
RNS Reactive nitrogen species 
SOD Superoxide dismutase 
SP-D Surfactant protein-D
TGF-β Transforming growth factor beta
Th17 T helper 17
Th2 T-helper 2 
TNF-α Tumor Necrosis Factor alpha
VEGF Vascular endothelial growth factor 
WA% Airway wall area percent
WHO World Health Organization
α1-AT Alpha 1 antitrypsin 
Introduction
Chronic obstructive pulmonary disease (COPD)
and asthma are chronic inflammatory airways’ dis-
eases both arising as major public health concerns
associated with a complex gene-environment inter-
action1.
COPD is a multicomponent disease character-
ized by a not fully reversible airflow limitation,
due to an abnormal inflammatory response to
noxious stimuli and linked to a range of patho-
logical changes such as mucus hypersecretion
and airway obstruction. In established disease the
inflammatory cell infiltrate is primarily repre-
sented by neutrophils and cytotoxic T cells1. 
COPD is currently a leading cause of morbid-
ity and mortality worldwide and a recent projec-
tion suggested it will become the 4th cause of
death in 20302.
Asthma is a common chronic inflammatory
disease characterized by bronchospasm and re-
versible airflow obstruction. The predominant
mechanism involved in the pathogenesis of asth-
ma is a Type 2 helper T cell cytokine-mediated
eosinophilic airway inflammation associated
with hyper-responsiveness of the lungs1,3.
The differential diagnosis between asthma
and COPD has been traditionally based on age of
onset, reversibility of airflow limitation, symp-
tom variability and atopy. Nevertheless, misclas-
sifications may occur because of the overlap of
clinical features1. 
Unfortunately early symptoms of COPD are
subtle and tend to be ignored by individuals, so
very often COPD is diagnosed at advanced
stages of disease when patients experience a sub-
stantial impairment of their quality of life4.
Spirometry is by far the more reliable diag-
nostic approach used to evaluate disease status,
and often the only one. Pulmonary function tests
reflect disease severity rather than disease activi-
ty and its measurements strictly depend on prop-
er execution and data interpretation. Moreover,
clinical symptoms on which pulmonologists rely
for a correct diagnostic approach are subjective
and nonspecific. Spirometry and clinical history
limitations have therefore encouraged focusing
on new indicators of disease.
Increased airways inflammatory response
may represent an early pathological event, and
markers of inflammation may play key roles both
in earlier diagnosis and evaluation of progno-
sis5,6. Efforts made in this field may also allow
substantial improvement in predicting respon-
siveness to therapy and/or evaluating efficacy of
therapy and disease activity7.
With this as a background, it is of primary impor-
tance to focus on improving early diagnostic meth-
ods, identifying patients with early COPD who could
benefit from non-pharmacologic treatments8.
In this review, we have analyzed markers of ear-
ly disease which may help to predict lung function
impairment and prognosis of COPD and asthma.
COPD and blood biomarkers
Although the observation that blood biomark-
ers could be measured by cost-effective and rou-
tinely used techniques makes this approach very
appealing, it is important to underline that mor-
bidities other than lung diseases may alter bio-
marker concentrations, making difficult to give a
clearcut meaning to their measurements5.
The biomarkers of systemic inflammation that
have been most widely studied are fibrinogen, in-
terleukin (IL)-6, IL-8, and C-reactive protein
(CRP)9. These markers can distinguish patients
with COPD from controls with acceptable sensitiv-
ity; however, unfortunately, they lack specificity6.
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Therefore, other molecules, such as extracel-
lular matrix markers such as metalloproteinases
(MMPs) 8 and 9 and lung-derived markers, in-
cluding surfactant protein-D (SP-D), clara cell
protein-16 (CC-16) and CCL-18 have also been
studied in order to identify proteins that could
better mirror the airway environment9. 
According to its definition, an ideal biomark-
er must be reproducible in stable disease. Among
blood markers, this has been the case of SP-D,
fibrinogen and CC-16, while other candidate
molecules, including IL-6 and IL-8, CCL-18 and
CRP, need further evaluation10.
SP-D is emerging as one of the promising
markers, being an important molecule involved
in pulmonary system immunity and surfactant
homeostasis: blood median levels of SP-D are
higher in COPD patients and in smokers. While
SP-D levels do not correlate with GOLD-defined
disease severity status, peak blood levels seem to
be linked to exacerbations risk and are associated
with extension of CT-documented emphysema
and its progression11,12.
Currently, another emerging biomarker for
COPD is fibrinogen, an acute phase plasma pro-
tein, which is synthetized primarily in the liver
and converted by thrombin into fibrin during
blood coagulation. According to Duvoix et al,
while there is a significant association between
fibrinogen levels and number of COPD exacer-
bations10,12, and rate of hospital admissions13,14,it
appears unable to predict lung function decline10.
Another predominant plasma biomarker is
CRP, a routinely measured acute-phase protein,
which is involved in COPD pathogenesis togeth-
er with other inflammatory molecules such as
matrix metalloproteinases. Although data need
further studies, it has been shown that CRP levels
at baseline are associated with lung function de-
cline and increases of this molecule are inversely
associated with forced expiratory volume in the
first second (FEV1). Similar findings were ob-
tained with other markers such as MMP-1, 7 and
9, not only in COPD associated to tobacco smok-
ing, but even in COPD due to biomass smoke ex-
posure15,16.
Fibronectin, a high molecular weight glycopro-
tein whose primary role is promoting wound re-
pair after injury, has been investigated as biomark-
ers in COPD, with controversial results. Accord-
ing to some authors, fibronectin seems indepen-
dently associated with mortality17, but these find-
ings are not confirmed by more recent studies. In
fact Kelly et al18 have studied the role of systemic
inflammatory biomarkers such as fibronectin, C-
reactive protein, and IL-6 in predicting COPD
mortality. Only C-reactive protein was proven to
be independently associated with increased risk of
death; while IL-6 has been shown to contribute to
mortality prediction only when added to known
clinical variables such as dyspnea, obstruction,
BMI, and exercise capacity index. 
Another recent study13 showed that the inci-
dence of hospital admissions for COPD was sig-
nificantly associated with increased levels of fib-
rinogen,  a1-antitrypsin, haptoglobin, ceruloplas-
min, and orosomucoid.
Studies on the relationship between markers
of eosinophilic and T cell activation and the de-
velopment of progressive COPD are promising.
In fact, IL-2 levels were higher in patients with
stable disease as compared to patients with pro-
gressive COPD. Moreover, Eotaxin-1 appeared
to be lower in patients with stable disease, sug-
gesting that both molecules may become impor-
tant markers of stability in patients with COPD19.
Airway remodeling in asthma and chronic ob-
structive pulmonary disease results in thickening
of bronchial walls and may affect lung function.
A significant correlation between CRP, IFN-gam-
ma, IL-6, and IL-13 and parameters measured by
high resolution computerized tomography, such
as wall area as a percentage of total airway area
(WA%), was recently demonstrated by Bon et
al20. On the contrary EGFR was inversely related
to this parameter but was able to reflect airway
functional impairment21.
Asthma and blood biomarkers
The management of asthma, as that of COPD,
has always been focused on the monitoring of
lung function using spirometric parameters such
as FEV1 and peek expiratory flow (PEF), possibly
adding the evaluation of airway hyper-responsive-
ness. Only recently, the identification of molecules
of airway inflammation as possible biomarkers of
clinical utility has been approached. Due to asth-
ma pathogenesis, the most widely investigated
markers are B-cell and T-helper 2 (Th2) derived
molecules7.
As recently discussed, high levels of blood
eosinophils indicate a switch to Th2 cell pheno-
type and may help to predict responsiveness to
corticosteroid therapy22.
A study by Wagener et al23 evaluated the role of
blood eosinophils, FE (NO) and serum periostin as
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surrogates for sputum eosinophils in asthma, show-
ing that blood eosinophils had the highest accuracy
value and suggesting that blood eosinophils evalua-
tion may facilitate asthma management and may
help the search for individualised treatment. 
In contrast, a previous research24 showed that
blood eosinophils, exhaled nitric oxide and total
IgE levels, despite being associated with sputum
eosinophils, did not accurately predict their per-
centages.
Periostin is a very promising molecule that re-
cently emerged as a potential biomarker of Th-2
dependent eosinophilic activation. Though not yet
applied in clinical practice nor accurately evaluated
in COPD or other airway diseases, the levels of pe-
riostin in blood seem to be strictly linked to airway
eosinophilia, even more than eosinophil count and
IgE levels25. Lately, Corren et al26 conducted a trial
on asthmatic adults in treatment with Lebrikizum-
ab, an anti-IL-13 monoclonal antibody, demon-
strating that higher levels of periostin are associat-
ed with a better response to therapy.
In this field special attention has been given
to Immunoglobulin E (IgE), as it is a marker for
B-cell activation26. 
Liang et al27 recently conducted an epigenome-
wide association study, surveying association of
total serum IgE concentration with methylation at
36 loci, which encode inflammatory mediators,
eosinophil products, and specific transcription fac-
tors. This study confirmed that methylation at
these loci was significantly different in
eosinophils from subjects with and without asth-
ma and high IgE levels, suggesting new biomark-
ers and therapeutic targets for atopic patients.
COPD and sputum biomarkers
Sputum represents an important diagnostic tool
for assessing airway inflammation in patients with
COPD. It can be spontaneous or induced by in-
halation of hypertonic saline solution28.
In contrast to other sampling procedures, such
as bronchoalveolar lavage, in which the main cell
type are the alveolar macrophage21, the typical
COPD feature in sputum is an increased number of
neutrophils although with not univocal findings.
While Shaw et al suggest29 a significant association
between neutrophil count and GOLD stage30, the
ECLIPSE study30 did not reveal a straightforward
correlation with pulmonary function.
While at all COPD stages we can find an acti-
vation of innate immunity, characterized by high-
er levels of neutrophils and macrophages, in later
stages, also lymphocytes seem to play a key
role31,32, with increased sputum concentrations of
type 1 CD-8+ T-cells21.
Interestingly some COPD patients have an in-
crease in eosinophil counts. Higher levels of
eosinophils seem to be associated with a better
responsiveness to corticosteroids and bronchodi-
lators33.
In the last years, the levels of an enormous
amount of molecules, released by activated respi-
ratory tract cells, such as cytokines, chemokines,
lymphokines, growth factors, molecules related
to oxidative stress, proteases and antiproteases,
have been found altered in the lungs of patients
with COPD. 
More than fifty cytokines have been identified
for being responsible of the inflammatory
process in COPD, and it appears to be a certain
overlap in their functions. More studies are need-
ed to clarify the role of each molecule in the
pathogenesis of COPD34,35.
Pro-inflammatory cytokines amplify and per-
petuate the inflammatory response, in part through
the activation of transcription factors that lead to
the increased expression of certain genes. Among
proinflammatory cytokines, several were found to
be increased in the sputum of patients with COPD,
(e.g. TNF-a, IL-b, and IL-6).
Tumor necrosis factor (TNF)-a is a pleiotrop-
ic cytokine that plays a significant role in chronic
bronchitis, COPD and asthma, but the analysis of
its levels yielded contrasting results. Some stud-
ies have shown that COPD cultured sputum cells
synthesize significantly less TNF-a than healthy
nonsmoking subjects, while no significant differ-
ences were found between sputum cells from
COPD patients and healthy smokers36. On the
contrary, Hacievliyagil et al37 found higher levels
of TNF-a in the sputum of COPD patients com-
pared to the smoking and non-smoking control
subjects, as also reported by Barnes34.
Interleukine (IL)-1a, IL-1 b, and IL-1 recep-
tor antagonist (IL-1RA) constitute the IL-1 su-
perfamily, involved in cell proliferation, differen-
tiation and apoptosis, and in the induction of
macrophage related cytokines and metallopro-
teinase MMP-9 release. Data on these molecules
are conflictual. According to recent studies, there
is an increase in the levels of this pro-inflamma-
tory cytokine in COPD patients sputum, which is
associated with disease severity. Moreover, a de-
crease in the levels of both IL1 receptor antago-
nist and soluble IL1 receptor was demonstrated38.
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On the other hand, Comandini et al36 report that
the expression of IL-1 in sputum bronchial cells
is present also in normal individuals, but data are
not sufficient to draw a clear role in tobacco
smoke exposed subjects.
Also IL-6 was recently studied, with the ob-
servation that its levels appear to be increased in
the sputum of COPD patients, primarily during
exacerbations39.
Chemokines have been observed in sputum
samples, as they play a key role in the recruit-
ment of inflammatory cells, especially
neuthophils, to the lungs of COPD patients:
CCL2, CXCL8, CXCL1 and CCL5 levels ap-
peared markedly increased in induced sputum of
patients with COPD40,41.
CXCL9, CXCL10 and CXCL11 correlate
with disease severity and are increased in sputum
of COPD patients. These findings were con-
firmed by Costa et al42 that analyzed their levels
in COPD patients and in normal volunteers.
In their review Comandini et al36 suggest that the
increased levels of chemotactic protein-1 (MCP-1)
and growth-related-oncogene-alpha (GRO-a) may
be related to an inflammatory state due to disease
process and not just to smoke exposure.
Some T-cell cytokines, also known as lym-
phokines, seem to be increased in the sputum of
individuals with advanced COPD31. IL-17A, pro-
duced by Th17 cells, a subset of CD4+ T cells,
was found to be increased in the sputum of indi-
viduals with COPD43. Similar findings were ob-
served for IL-18, with data also related to disease
severity44.
Several growth factors have been studied in
sputum samples of patients with COPD. Profita
et al36 demonstrated higher levels of granulocyte-
macrophage colony stimulating factor (GM-CSF)
in induced sputum cells of COPD patients, while
data on sputum induced transforming growth fac-
tor (TGF)-b are still scarce28.
Vascular endothelial growth factor (VEGF)
was found to be increased in induced sputum of
patients with COPD and its levels were negative-
ly correlated with lung function45.
Among oxidants and oxidative stress related
factors, several molecules have been studied in
their association with COPD in sputum samples.
Myeloperoxidase (MPO) is contained in neu-
trophils granules and in monocytes. According to
a recent metanalysis, its sputum levels were
higher during exacerbations and in stable disease
in comparison to normal controls46. Superoxide
dismutase (SOD) has been more intensively stud-
ied using other sampling procedures, while there
are not enough data on sputum28. 
8-isoprostane is an important prostaglandin-
isomer, which is emerging as a relevant marker
associated to the physiopathology of oxidative
damage. According to Kinnula et al46, 8-iso-
prostane increases in the sputum of COPD pa-
tients and is correlated with smoking attitude and
with the reduction of FEV1 and FEV1/FVC.
Levels of nitrotyrosine are considered to be
reliable indicators of the production of Reactive
nitrogen species (RNS), due to higher levels of
NO during airway inflammation. Nitrotyrosine
levels are increased in the induced sputum of
smokers, as documented by Rityla et al46.
With regard to proteases and antiproteases,
matrix metalloproteinases (MMPs) are involved
in the destruction of extra cellular matrix compo-
nents, and their levels have been accurately stud-
ied in the sputum of patients with COPD. Ilumets
et al48 suggest that MMP-8 can differentiate
symptomatic smokers and individuals who risk
to develop COPD among non-symptomatic
chronic smokers. Moreover, MMP-8 also seems
to be associated with lung function. Also MMP-9
and MMP-12 appear increased in symptomatic
smokers but neither of them accurately differen-
tiate healthy from symptomatic smokers.
Neutrophil elastase (NE) is a neutrophilic ser-
ine protease, and its enzymatic activity appears
to be considerably increased in current smokers
versus former smokers with COPD49. Paone et
al50 confirmed an increased concentration of NE
in the sputum of patients with COPD, and
demonstrated an increase of HNP (Human Neu-
trophil Peptide), IL-8 and MMP-9. Furthermore
NE, IL-8, and HNP, seemed to have a significant
negative correlation with FEV1 and FEV1/FVC. 
Concerning leukocyte pro-inflammatory and
antibacterial products, one of the main molecules
that have been studied in sputum is leukotriene B4
(LTB4), an arachidonic-derived molecule released
by both neutrophils and macrophages. Tufvesson
et al showed that sputum levels of LTB4 could be
reliable predictors of COPD exacerbations51.
Another approach in biomarker classification
has been proposed by Comandini et al36, who strat-
ified biomarkers into five principal groups: 1) mol-
ecules that are associated both with tobacco smoke
and COPD, such as MMP-9, MMP-8, LTB4, GM-
CSF and 8-isoprostane; 2) COPD biomarkers that
are not in association with tobacco smoke, such as
IL-8, a1-AT, and GRO-a; 3) biomarkers that are
influenced by tobacco smoke exposition but are
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not correlated with COPD activity (NE, CXCL9,
CXCL10, CXCL11 and CCL5); 4) markers that
are negatively associated with COPD and/or tobac-
co smoke, such as TGF-b and SOD; 5) biomarkers
that are variably associated with COPD and tobac-
co smoke (TNA-a, MPO, and VEGF).
Asthma and sputum biomarkers
Sputum analysis is also a remarkable tech-
nique applied to investigate respiratory tract in
patients with asthma. Since asthma is not associ-
ated with productive cough, it is often necessary
to perform sputum induction. 
Asthma is traditionally considered as a preva-
lent eosinophilic disease so that several Authors
have suggested to apply eosinophil counts to
support diagnosis52. Because cases of non-
eosinophilic asthma may exist, as well as patients
showing eosinophilic predominant COPD: stud-
ies on induced sputum have led to the definition
of four inflammatory phenotypes of asthma:
eosinophilic, neutrophilic, mixed and paucigran-
ulocytic pattern53. 
Recent observations54 pointed out that pa-
tients with higher numbers of sputum eosinophils
seem to have better responsiveness to steroid
therapy. Moreover, Petsky et al55 carried out a
meta-analysis in which asthma exacerbations re-
sulted prevented by treatment protocols based on
sputum eosinophil counts rather than clinical
symptoms. However, other trials did not confirm
these results56.
Another potential sputum biomarker for asth-
ma is eosinophil cationic protein (ECP). It is an
eosinophil-derived degranulation product that is
released during several inflammatory conditions,
therefore does not represent a specific marker of
asthmatic disease57. Nevertheless, in patients
with asthma diagnosis, ECP levels could be used
for the assessment of the extension and severity
of inflammation58. In addition, VEGF appears in-
creased in sputum during asthmatic exacerba-
tions and high levels of VEGF in sputum seem to
be related to airflow obstruction59.
COPD and biomarkers 
in BAL
Besides sputum and blood samples, potential
useful COPD biomarkers have been evaluated us-
ing broncoalveolar lavage (BAL), such as several
pro and anti-inflammatory molecules sampled
from the lower respiratory tract. 
Importantly, several shortcomings must be
considered: COPD inflammation may alter the
characteristics of alveolar fluid making it quanti-
tatively inappropriate for analysis; the exact
amount of biomarkers may be difficult to mea-
sure due to sample dilution because of saline so-
lution lavage21. In addition, the effectiveness of
the results could be limited by manipulation dur-
ing BAL processing33,39. Thus, the validation of a
diagnostic protocol based on BAL requires a sig-
nificant number of patients.
As BAL analyzes distal airways, there is a
high prevalence of alveolar macrophages in the
cell count of COPD patients (>80%)60, but, inter-
estingly, Drost et al61 found that a severe stage of
disease might be associated with mononuclear
cell reduction. Of note, smokers show a de-
creased quote of lymphocytes as compared to ex-
smokers60. In particular, while the amount of CD-
8+ T-cells appears higher, CD-4+ T-cells number
is lower in COPD smokers and healthy smokers
compared to non-smoking subjects. It is difficult
to gather data about eosinophils; however, some
studies demostrated a higher number of this cell
type in COPD60.
COPD pathogenesis is linked to neutrophils
and their amount in the BAL correlates with
FEV1/FVC ratio61. In fact, there is a rise of both
neutrophils and their derived molecules levels
during stable status and also during exacerba-
tions, compared to healthy nonsmokers. This is
probably due to smoking exposition, as some
studies document60. Notably, in mild emphyse-
ma, this cell type cannot be detected in BAL,
even though in BAL fluid neutrophil derived en-
zymes and neutrophil chemokine IL-8 are higher
than in healthy condition60.
Rohuani et al62 found that NE baseline levels
in BAL from individuals with alpha 1 antitrypsin
deficiency correlates with FEV1 rate of decline.
BAL fluid is a source of different molecules
which may be detected in order to analyze respi-
ratory tract inflammation. Paone et al63 found
that human neutrophil peptides (HNP), small an-
timicrobial molecules released by activated neu-
trophils, are increased in smoker BAL. 
COPD causes a rise of surfactant protein D (SP-
D) in serum but a decrease of this molecule in BAL
whereas steroid treatment leads to an opposite con-
dition. For this reason, SP-D may be considered a
marker of both COPD and response to therapy33.
Miller et al64 demonstrated that some eosinophil
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markers in BAL such as eosinophil cationic protein
(ECP) and eotaxin were associated with emphyse-
ma extension reported in CT scan and they were
higher in COPD patients after bronchodilator thera-
py, in contrast to neutrophil marker levels. In addi-
tion, healthy smokers have higher BAL levels of
ECP, myeloperoxidase and IL-8 in comparison with
nonsmokers. However, it is useful to underline that
increased ECP and MPO levels are found also in
other chronic respiratory disorders65,66.
Another interesting finding is that
prostaglandin D2 and eicosapentaenoic acid lev-
els in BAL lavage are positively correlated with
lung function in COPD patients67. Antczak et al68
also demonstrated positive correlations between
8-isoprostane and LTB4 amount in BAL.
Among studies on COPD biomarkers, some
authors investigated an innovative research field,
the regulation of gene expression involved in
lung inflammation. In BAL lavage, basic salivary
proline-rich protein 4 (PRB4) and lysozyme C
have been reported to be up-regulated in smok-
ers, neutrophil defensins 1 and 2 (DEFA) were
positively associated to COPD, and transcription
of calgranulina A gene has been found after
smoke exposition, both in patients with and with-
out COPD. On the other hand, salivary acidic
proline-rich phosphoprotein 1/2 (PRH1 and
PRH2) and clara cell phospholipid binding pro-
tein (CC10) showed a reduced expression69.
Tobacco smoke is by far the most commonly
encountered risk factor for COPD; however, not
all smokers develop clinically significant COPD.
This suggests that cigarette smoking cannot be
the only cause of COPD and that additional fac-
tors are involved in determining each individual
susceptibility. According to Dahl et al5 the earli-
est potential risk factors of developing obstruc-
tive lung diseases are due to genetic predisposi-
tion, and as suggested by a meta-analysis by
Joanna Smolonska70 on suspected obstructive air-
way diseases genes, a polygenic inheritance
seems involved, with each gene having a small
effect on the development of the disease.
In addition, COPD is a progressive disease
and it is demonstrated to begin many years be-
fore a diagnosis is made, so focusing on indica-
tors of earlier diagnosis and treatment is of pri-
mary importance71.
At present, spirometry is the most reliable de-
tection method for obstructive pulmonary dis-
eases; however, airway obstruction does not seem
to correspond to the very beginning of the dis-
ease71.
When spirometry is used as the only method
of analysis, all the other pathological compo-
nents of such multicomponent diseases remain
ignored5. New proven diagnostic tests are there-
fore needed in order to allow an early and com-
plete disease assessment.
An earlier diagnosis would bring several ad-
vantages, including the use of therapy when it
would have a good chance to modify the course
of the disease. Therefore, the identification of bi-
ological markers of susceptibility or progression
of disease would be crucial. 
In this background, and considering the key
role of aberrant inflammatory response in the lung
as a primary pathogenic process of obstructive air-
way diseases, inflammatory markers have a
promising predictive value in COPD and asthma5.
Although an overwhelming number of bio-
markers has been proposed in airways diseases,
there are still many unanswered questions about
their utility in “real life”. 
One of the most widespread definition of a
biomarker is that of a molecule of clinical utility
by being associated with an alteration in physiol-
ogy or progression of disease.
Several characteristics distinguish an ideal bio-
marker: its association with disease, the demonstra-
tion that therapy has a consistent effect on the
marker concentrations and the observation that
these changes are associated with positive effects in
clinical outcomes. Other necessary feature is that of
being easily measured using standard procedures72.
The identification of potential markers of air-
way diseases is, therefore, one of the most chal-
lenging aims of research5 and markers of pul-
monary diseases will be very useful in the up-
coming future especially in predicting prognosis
and responsiveness to treatment34.
However, as Dahl et al5 notice, biomarkers
may be contemporarily associated to various
pathogenic processes, possibly representing dis-
eases other than COPD, making more difficult
the interpretation of the results.
An interesting suggestion offered by Tzortzaki et
al73 is to combine panels of markers together to
achieve higher specificity. This alternative approach
would confer clinical utility to markers that current-
ly are not sufficiently specific to be used alone. 
Paone et al74 evaluated a panel of sputum
markers such as HNP, MMP-9, and IL-8 analyz-
ing its diagnostic role in discriminating COPD
patients from smokers.
As underlined by Ptolemi et al75, special atten-
tion must be given to cost benefit ratio, as the
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number of NIH grants from 1986 to 2009 for bio-
marker research has enormously increased with-
out comparable findings of clinical utility, espe-
cially in the latest years.
Conclusions
Although at the present the knowledge about
reproducibility is too immature and very few
markers have been validated, there is urgency to
approve obstructive pulmonary disease biomark-
ers to give consistent help to clinicians in achiev-
ing a complete and prompt assessment of pa-
tients, including diagnosis, follow-up and re-
sponse to therapy76.
Recently proteomics approach, by the associ-
ation between different protein profiles and path-
ogenic processes, is gaining an important role in
pulmonary medicine allowing a more precise dis-
crimination between patients with different out-
comes and response to therapy. Lee et al77 under-
take proteomic analysis in lung tissues of smok-
ers, nonsmokers, and COPD patients demonstrat-
ing a significant difference in the three groups.
It is likely that an integrative approach that
combines biomarkers with clinical parameters,
associated with new information from the fields
of genomics, transcriptomics, and proteomics,
will improve the ability of clinicians in monitor-
ing obstructive lung diseases progression and
predicting their response to therapy78.
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